SCHEMBL2895063

SCHEMBL2895063

NC1CCCC1c1c[nH]cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vuf-5296 SCHEMBL8846403 0.80
Vuf-5297 SCHEMBL7508989 0.80
Vuf-5296 SCHEMBL8846552 0.80
Vuf-5296 SCHEMBL6136537 0.80
Vuf-5296 SCHEMBL7784076 0.80
SCHEMBL9044336 0.74
SCHEMBL17604203 0.70 HRH4 (0.36)
SCHEMBL5827852 0.70
SCHEMBL232190 0.69
SCHEMBL18998725 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137391-A1 Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder MSD K.K. (JP) 2010-06-03 US claimed
EP-1938838-A1 HISTAMINE H3 AGONIST FOR USE AS THERAPEUTIC AGENT FOR LIPID/GLUCOSE METABOLIC DISORDER BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-07-02 EP claimed
US-20100137391-A1 Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder MSD K.K. (JP) 2010-06-03 US disclosed
EP-1938838-A1 HISTAMINE H3 AGONIST FOR USE AS THERAPEUTIC AGENT FOR LIPID/GLUCOSE METABOLIC DISORDER BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-07-02 EP disclosed